Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
  • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
  • A61K33/30—Zinc; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
  • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to a fixed-dose association of phytate and zinc in synergic proportions for use in the treatment of crystallisation of hydroxyapatite .
• the invention also relates to the utilisation of said association for manufacturing a drug for the treatment, prophylaxis and/or prevention of crystallisation of hydroxyapatite in humans.
• any process of pathological crystallisation is a consequence of an imbalance between three groups of factors: supersaturation, crystallisation promoters (basically heterogeneous nucleants) and repressors of crystallisation (crystallisation inhibitors and cellular defence mechanisms) .
• a system is supersaturated in relation to a solute when it contains it in amounts exceeding the amount established by its solubility product. It is thus a thermodynamic factor and is only a kinetic question (i.e. of the time elapsed) that the corresponding solid will be finally formed.
• the promoters or heterogeneous nucleants are substances that facilitate the formation of the crystal, reducing the induction period by preventing the stage of homogeneous nucleation. These are thus kinetic factors.
• the inhibitors of crystallisation are substances that hinder or prevent the development of crystals. They can act at the nucleation level (by adsorbing on the homogeneous or heterogeneous nucleus being formed) , of crystalline growth (by adsorbing on the faces of the crystal being formed) or of both processes at once. It therefore also includes kinetic factors.
• Myo-inositol hexaphosphate is the most powerful inhibitor known of the development of calcium salts, and acts on the heterogeneous nucleation of the calcium oxalate, on the crystalline growth of the calcium oxalate and on homogeneous and heterogeneous nucleation of calcium phosphate.
• the phytate together with the pyrophosphate, shows inhibitory effects both on the crystallisation of brushite and crystallisation of hydroxyapatite . Both compounds constitute two of the forms in which the calcium phosphate can crystallise, this last being a majority component of pathological vascular mineralisations .
• phytate is present in all the organs, tissues and biological fluids of mammals, the human being among them. It has further been shown that most extracellular phytate found in organs, tissues and fluids of mammals has a dietary origin and is not the result of endogenous synthesis, whereas intracellular phytate (found in very much lower concentrations) is probably produced inside the cell. Its levels in the organism are therefore directly related to the exogenous supply thereof, either through dietary ingestion or topical application.
• Blood plasma is always supersaturated in relation to calcium phosphate, due to the concentration values of phosphate, calcium and its pH . Indeed, calcifications are frequently found in the cardiovascular system, reducing the flexibility of the blood vessels and promoting thrombosis and arterial rupture. When such calcifications appear in the cardiac valves, they are associated with various disorders which, if not corrected, can lead to heart failure and death.
• cardiovascular calcifications can start by as early as the second decade of life, and that coronary calcifications affect 50% of people aged between 40 and 49 years, and 80% of people aged between 60 and 69 years.
• hydroxyapatite is also accumulated in the buccal cavity through mineralisation of the dental bacterial plaque.
• Dental bacterial plaque is a deposit on the teeth that cannot be removed with water under pressure or simply by rinsing out the mouth. Brushing does help to prevent a speedy accumulation of such deposits, but even a regular brushing is not enough to remove all the deposits that adhere to the teeth.
• the plaque that adheres to the surface of the tooth can calcify (calcified dental plaque) to form dental tartar or calculus.
• the plaque is therefore a precursor of calculus.
• the plaque can be formed on any part of the surface of the tooth, particularly on the gingival margin. Therefore the presence of plaque on the teeth, in addition to being unsightly, can be a precursor to the development of gingivitis and periodontal diseases.
• the tartar or calculus are calcified deposits on the teeth which are formed due to mineralisation of the plaque, a process that starts within a period of 24-72 hours and takes an average of 12 days to reach maturity.
• HAP hydroxyapatite
• the formation of calculi takes place in two steps.
• the bacterial plaque is deposited on the teeth, being made up of living and dead bacteria surrounded by a gellified matrix derived from bacteria and saliva.
• said plaque undergoes a process of mineralisation until forming the dental calculus.
• amorphous calcium phosphate begins to be deposited on and within the extracellular matrix of the dental plaque, which becomes sufficiently packed for the aggregates to be resistant to deformation, in the end turning into the crystalline HAP material.
• the amorphous calcium phosphate though related to the HAP, differs from it in its crystalline structure, particle morphology and stoichiometry .
• HAP formation has been tested by means of the action of inhibitors, sequestrants, efficient suppressors of calcium and magnesium ions and/or chelating agents.
• Dehydrated polyphosphates such as water-soluble hexametaphosphates, tripolyphosphates, pyrophosphates and the like have been used for this purpose.
• US patent US5300289 describes antimicrobial oral compositions with phytate for mouth care.
• the oral compositions described contain phytic acid or pharmaceutically acceptable salt thereof, a cationic antimicrobial compound and compatibilizing agent for the control of the dental calculus, dental plaque, gingivitis, periodontitis and/or bad breath.
• composition comprising: (1) from 0.001 to 10% by weight of one or more compounds having C-O-P bonds, where the compound having the C-O-P bond is myo-inositol hexakis (dihydrogen phosphate) , myo-inositol pentakis (dihydrogen phosphate) , myo-inositol tetrakis (dihydrogen phosphate) or a physiologically acceptable salt thereof; (2) 0.001 to 10% by weight of one or more cationic antimicrobial compounds; and (3) 0.1 to 20% by weight of one or more compatibilizing agents.
• a cationic antimicrobial compound a list of 10 possible compounds or derivatives thereof is disclosed.
• the compatibilizing agents are chosen from acids and their alkaline metal salts or alkaline earth metal salts, or mixtures thereof. It is also disclosed that the presence of a metallic ion selected from strontium, magnesium, tin, zinc, calcium or mixtures thereof in the aforesaid composition does not lead to precipitation of the phytic acid of the composition in solution and, therefore, the addition thereof to the above composition will help to suppress bad breath.
• the molar ratio between said metallic ion and the phytic acid can be present in an oral composition from 4:1 to 1:4, preferably from 3:1 to 1:3 and still more preferably, in a 1:1 ratio.
• compositions comprising different combinations of antiplaque and antigingivitis agents, together with or optionally together with other compounds such as for example anticalculus agents whose purpose is to eliminate the bacterial etiology and risk factors.
• the problem to be solved by the present invention may be posed as an alternative way for inhibiting the crystallisation of hydroxyapatite in human beings, with surprising effects, in particular on the development of dental calculi and on calcification of hydroxyapatite in arteries, veins, heart, brain, lung and skin.
• the solution is based on a fixed-dose association of phytate and zinc with synergic effects on the inhibition of hydroxyapatite crystallisation.
• the combination of phytate and zinc has not been described as a synergic mixture against crystallisation of hydroxyapatite and there is not any explanation of the synergic effect between the phytate and zinc giving rise to an increased inhibiting effect on crystallisation of the phytate against hydroxyapatite.
• phytate or "myo- inositol hexaphosphate” is taken to mean the molecule corresponding to the formula:
• inhibitor of crystallisation is taken to mean a substance that is capable of reducing or preventing the formation of mineralisations .
• cardiovascular mineralisation is taken to mean any solid concretion accumulated on the wall of a blood vessel or any part of the heart .
• the general object of the present invention is to inhibit the formation of hydroxyapatite .
• Said salt forms mineralisations in the organism which, in general, can be prevented or reduced by the phytate present in the organism.
• a composition, mixture or treatment that effectively permits the external inhibition of hydroxyapatite crystallisation.
• the present invention provides an association of phytate and Zn 2+ for the treatment, prevention and/or prophylaxis of the formation of hydroxyapatite in the cardiovascular system and buccodental cavity.
• the present invention provides an association of phytate and Zn 2+ for the treatment, prevention and/or prophylaxis of the formation of hydroxyapatite in the joints, mammary glands, kidney, brain, lung and skin, since the inhibition of crystallisation of a salt in a soft tissue depends on the concentration of inhibitor that can be reached in said tissue.
• concentrations of phytate in soft tissues are similar (and in the brain are 10 times higher), so that in these soft tissues the same effect is expected as in cardiovascular tissue.
• the authors of the present invention have found that the presence of zinc in an association of phytate and zinc leads to an increase of the inhibiting effect on the crystallisation of the phytate itself (while the zinc alone has no inhibiting effect on the crystallisation of hydroxyapatite) .
• the zinc is adsorbed on the nucleus being formed or the crystal undergoing growth of hydroxyapatite.
• the affinity of the phytate for the zinc exceeds that for calcium, the adsorption of zinc on hydroxyapatite increases the affinity of the phytate for the nucleus being formed or the crystal undergoing growth, enhancing its inhibiting effect on crystallisation.
• a molar ratio of 5:1 after 10 minutes of crystallisation induction period gives rise to an increased inhibiting effect on crystallisation of phytate of the order of 50% (see Figure 2) .
• the objective in this case is to increase the inhibiting capacity of the saliva against the crystallisation of calcium salts and to prevent complications of formation of calcium biomineralisations by using an oral composition comprising an association of phytate and Zn 2+ .
• the basis for the use of a mouthwash with phytate and Zn 2+ is the reduction of the risk of formation of hydroxyapatite biomineralisations, and it is grounded on the following facts :
• Phytate is a very powerful inhibitor of homogeneous and heterogeneous nucleation and crystalline growth of hydroxyapatite and other calcium phosphates. A consequence of this action is the inhibition of the crystallisation of hydroxyapatite, while the development of microparticles of calcium phosphate adhering to the tooth is prevented.
• Phytate is found in human saliva, the concentration thereof varying depending on the diet of the individual .
• Phytate has the advantage of being a natural product present in human saliva more resistant to the action of the salivary phosphatases than other linear polyphosphates .
• any pharmaceutical form whether it be a mouthwash, a vitamin supplement or other form of administration comprising a synergic association of phytate and Zn 2+ in accordance with the present invention is included in the scope thereof.
• Figure 1 shows the effect of an association of phytate and Zn 2+ on hydroxyapatite in vitro.
• the first curve corresponds to direct precipitation without phytate or Zn 2+ .
• the second (Zn 2+ ) consists of the addition of 0.038 ⁇ M of Zn 2+ .
• the third curve corresponds to the precipitation of hydroxyapatite in the presence of 0.38 ⁇ M of phytate.
• a significant inhibiting effect on crystallisation is shown.
• the last graph corresponds to the precipitation in the presence of 0.38 ⁇ M of phytate and 0.038 ⁇ M of Zn 2+ (phytate-Zn molar ratio 10:1). It can be observed that the precipitation of hydroxyapatite is totally inhibited. Moreover, this is not an additive effect, but a synergic effect, since the Zn alone does not show any inhibiting effect.
• Figure 2 shows the effect of an association of phytate and Zn 2+ on hydroxyapatite in vitro.
• the first series corresponds to the direct precipitation without phytate or Zn 2+ .
• the second consists of the addition of 0.3 ⁇ M of Zn 2+ .
• the third series corresponds to the precipitation of hydroxyapatite in the presence of 1.5 ⁇ M of phytate. A significant inhibiting effect on crystallisation is shown.
• Figure 3 shows the effect of an association of phytate and Zn 2+ on the hydroxyapatite formed in human aortic valves implanted in Wistar rats.
• a statistically significant reduction of the degree of calcification in valves can be observed in the group treated with a diet containing phytate + Zn 2+ in relation to the control group treated with a diet without phytate.
• the animals were randomly divided into two groups of 6 rats, a control group, treated only with Zn 2+ , fed with the AIN-76A diet (a purified diet lacking in phytate and with 0.003% of Zn 2+ ) and a group treated with the same diet but with a supplement of 1% of phytate in the form of calcium- magnesium salt (phytate-Zn 2+ molar ratio 30:1).
• AIN-76A diet a purified diet lacking in phytate and with 0.003% of Zn 2+
• AIN-76A diet a purified diet lacking in phytate and with 0.003% of Zn 2+
• a group treated with the same diet but with a supplement of 1% of phytate in the form of calcium- magnesium salt phytate-Zn 2+ molar ratio 30:1
• the urinary levels of phytate at the end of the study were statistically lower in the control group (0.08 +/- 0.03 mg/1) than in the treated group (1.22 +/- 0.24 mg/1) .
• the implantation of these valve fragments led to the development of calcifications of calcium phosphate (hydroxyapatite) on the surface of and inside the valve.
• a statistically significant reduction of the degree of calcification of the aortic valve implanted in the group treated with phytate + Zn 2+ was shown when compared with the control group (see Figure 3) , thus proving that plasma phytate is capable of inhibiting the development of calcifications of hydroxyapatite formed in human aortic valves implanted in Wistar rats.
• Example 4 Firstly, it was decided to evaluate the effect of phytate on the formation of hydroxyapatite in the buccodental cavity. A patient was submitted to two different treatments for one week (Table 1), with two daily administrations of 10 ml of one or the other mouthwashes. A qualitative evaluation was made of the mineralised deposits in the buccodental cavity, and a significant visual reduction of tartar or dental calculus was shown.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Inorganic Chemistry (AREA)
• Urology & Nephrology (AREA)
• Rheumatology (AREA)
• Physical Education & Sports Medicine (AREA)
• Molecular Biology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Vascular Medicine (AREA)
• Hematology (AREA)
• Neurosurgery (AREA)
• Dermatology (AREA)
• Biomedical Technology (AREA)
• Obesity (AREA)
• Pulmonology (AREA)
• Neurology (AREA)
• Diabetes (AREA)
• Endocrinology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Cosmetics (AREA)
• Catalysts (AREA)
• Adhesives Or Adhesive Processes (AREA)
• Dental Preparations (AREA)

Priority Applications (14)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=38007006

Family Applications (1)

Country Status (18)

Cited By (2)

Families Citing this family (6)

Citations (11)

Family Cites Families (16)

• 2006
  • 2006-02-17 ES ES200600377A patent/ES2280136B1/es not_active Expired - Fee Related
• 2007
  • 2007-02-14 MX MX2008010502A patent/MX2008010502A/es active IP Right Grant
  • 2007-02-14 PT PT07726369T patent/PT1984001E/pt unknown
  • 2007-02-14 DK DK07726369.7T patent/DK1984001T3/da active
  • 2007-02-14 BR BRPI0707008-0A patent/BRPI0707008A2/pt not_active Application Discontinuation
  • 2007-02-14 EP EP07726369A patent/EP1984001B1/en active Active
  • 2007-02-14 CN CN200780005915XA patent/CN101384266B/zh not_active Expired - Fee Related
  • 2007-02-14 RU RU2008138358/15A patent/RU2415673C2/ru not_active IP Right Cessation
  • 2007-02-14 WO PCT/EP2007/051413 patent/WO2007093611A1/en not_active Ceased
  • 2007-02-14 US US12/279,616 patent/US8377908B2/en not_active Expired - Fee Related
  • 2007-02-14 AT AT07726369T patent/ATE516035T1/de active
  • 2007-02-14 CA CA2641216A patent/CA2641216C/en not_active Expired - Fee Related
  • 2007-02-14 PL PL07726369T patent/PL1984001T3/pl unknown
  • 2007-02-14 AU AU2007216453A patent/AU2007216453B2/en not_active Ceased
  • 2007-02-14 SI SI200730738T patent/SI1984001T1/sl unknown
  • 2007-02-14 JP JP2008554771A patent/JP5554499B2/ja not_active Expired - Fee Related
• 2008
  • 2008-09-11 NO NO20083901A patent/NO341286B1/no not_active IP Right Cessation
• 2011
  • 2011-10-06 CY CY20111100955T patent/CY1111913T1/el unknown
• 2013
  • 2013-02-19 US US13/770,782 patent/US9144578B2/en active Active
• 2014
  • 2014-02-10 JP JP2014023681A patent/JP5908933B2/ja not_active Expired - Fee Related

Patent Citations (12)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events